Phase 3 Clinical Trials With Primary Completion Dates in September 2023
This is a list of Phase 3 trials with primary completion dates in September 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AEZS | Aeterna Zentaris Inc. | 2023-09-01 | Phase 3 | NCT04786873 | A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is |
| ARQT | Arcutis Biotherapeutics, Inc. | 2023-09-01 | Phase 3 | NCT04286607 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis |
| CYTK | Cytokinetics, Incorporated | 2023-09-01 | Phase 3 | NCT05186818 | CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM |
| FSPKF | Fisher & Paykel Healthcare Corporation Limited | 2023-09-01 | Phase 3 | NCT05505279 | Ventilatory Effects of THRIVE During EBUS |
| IMGN | ImmunoGen, Inc. | 2023-09-01 | Phase 3 | NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
| MMSI | Merit Medical Systems, Inc. | 2023-09-01 | Phase 3 | NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant |
| NVCR | NovoCure Limited | 2023-09-01 | Phase 3 | NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) |
| NVCR | NovoCure Limited | 2023-09-01 | Phase 3 | NCT03940196 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) |
| XENE | Xenon Pharmaceuticals Inc. | 2023-09-01 | Phase 3 | NCT04912856 | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE |
| ZYNE | Zynerba Pharmaceuticals, Inc. | 2023-09-01 | Phase 3 | NCT04977986 | Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome |